reports hero background
Updated: Nov 21, 2026
ADRX Logo

Adarx Pharmaceuticals

NASDAQ:ADRX·Stock Analysis Report
Day Range
$12.63 - $14.87
Market Cap
1.57B
P/E Ratio
0.0000
Avg Value
$17.24
Year Range
$12.70 - $21.77
$12.79-$1.37 (-9.68%)
1
General Information
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases.

Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.

2
Adarx Pharmaceuticals (ADRX) Stock Graph
3
How We Grade Adarx Pharmaceuticals (ADRX)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade Adarx Pharmaceuticals (ADRX) across the board compared to its closest peers.

4
Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

5
Peer Ratings

See how Adarx Pharmaceuticals compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers
Value
Quality
Growth
Momentum
Short
Medium
Long
URGNUroGen Pharma
N/A
N/A
N/A
61.02
KRSAKorsana Biosciences
N/A
N/A
N/A
N/A
RXRXRecursion Pharmaceuticals
N/A
N/A
N/A
N/A
SRPTSarepta Therapeutics
N/A
N/A
N/A
15.57
Short: price trend over the last couple of months
Medium: price trend over the last couple of quarters
Long: price trend over the past year
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
6
Future Growth
Our estimate of future price growth is based on 1 analyst rating over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $32.00 - $38.00 with an average of $35.25

175.61%
Expected movement for Adarx Pharmaceuticals (ADRX) over the next 12 months
Based on these rankings

Recent Ratings for Adarx Pharmaceuticals (ADRX)

JP Morgan
Date:
Nov 19, 2026
Action:
Maintains
Prev. Target:
$38.00
New Target:
$36.00
7
Financial Health
What is the current state of the company's financial situation?

We measure the health of a company based on how profitable they are and their ability to cover both their short-term and long-term debts. The key indicators that we use are the Operating Margin, Quick Ratio, and Debt-to-Equity ratio relative to the companies peers

Operational Margin -14.5138

The operating margin measures how much profit a company makes after it spends money on wages, materials or other administrative expenses but before interest and taxes. It is a good representation of how efficiently a company is able to generate profit from its core operations.

Quick Ratio 20.6776

The quick ratio measures how much of a company's debt, that is due in less than 1 year, can be covered using its cash equivalents, marketable securities, and money that is currently owed to them (accounts receivables).

A company with a quick ratio of less than 1.00 does not, in many cases, have the capital on hand to meet its short-term obligations if they were all due at once, while a quick ratio greater than one indicates the company has the financial resources to remain solvent in the short term.

Debt-to-Equity 0.6174

Debt-to-equity is calculated by dividing a company's total liabilities by its shareholders equity. It is a measure of the degree to which a company is financing its operations through debt versus wholly owned funds. Generally speaking, a D/E ratio below 1.0 would be seen as relatively safe, whereas ratios of 2.0 or higher would be considered risky.

The chart above shows Adarx Pharmaceuticals (ADRX) operating margin, quick ratio, and debt-to-equity ratio compared to its peers. The black markers represent the peer averages for each ratio and the blue bars represent Adarx Pharmaceuticals (ADRX) ratio values.